Hypotensive peptides from milk proteins

Area of Science:

• Cardiovascular Science
• Nutritional Biochemistry
• Pharmacology

Background:

• Hypertension is a primary modifiable risk factor for cardiovascular disease (CVD), contributing to conditions like myocardial infarction and stroke.
• Antihypertensive medications, targeting the renin-angiotensin-aldosterone system, incur significant healthcare costs and are associated with various side effects.
• Milk proteins, including caseins and whey, are recognized sources of bioactive peptides with potential therapeutic properties.

Purpose of the Study:

• To explore the potential of milk protein-derived peptides as a natural antihypertensive agent.
• To investigate the role of these peptides in modulating the renin-angiotensin-aldosterone system.
• To assess the implications for reducing cardiovascular disease burden and healthcare expenditure.

Main Methods:

• Review of existing studies on milk protein peptides (casokinins, lactokinins) and their effects on blood pressure.
• Analysis of the mechanism involving inhibition of angiotensin-I-converting enzyme (ACE).
• Examination of evidence from animal models (spontaneously hypertensive rats) and limited human trials.

Main Results:

• Milk protein-derived peptides, specifically casokinins and lactokinins, demonstrate ACE inhibitory activity.
• Studies in hypertensive rats show significant reductions in blood pressure.
• Preliminary human studies indicate statistically significant hypotensive effects, lowering both systolic and diastolic pressures.

Conclusions:

• Milk protein-derived peptides represent a promising functional food ingredient or nutraceutical for blood pressure management.
• This natural approach has the potential to mitigate the risks and costs associated with hypertension and cardiovascular disease.
• Further research and development could lead to significant global healthcare cost savings.